Yu-hsuan Shih

Taitung, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".

Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: May 10, 2026

Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort".

Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: May 03, 2026

Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.

Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.

Journal: Therapeutic advances in medical oncology

Published: September 28, 2025

Lymph Node Ratio as a Risk Factor for Early Recurrence in Older Patients with Stage II/III Gastric Cancer: A Retrospective Study.

Lymph Node Ratio as a Risk Factor for Early Recurrence in Older Patients with Stage II/III Gastric Cancer: A Retrospective Study.

Journal: Journal of clinical medicine

Published: August 12, 2025

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

Journal: British journal of cancer

Published: August 05, 2025

Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network.

Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network.

Journal: Therapeutic advances in medical oncology

Published: August 02, 2025

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort.

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: June 08, 2025

Impact of Systemic Lupus Erythematosus (SLE) on Short-Term Outcomes of Cholecystectomy for Acute Cholecystitis: An Analysis of the US National Readmission Database, 2016-2020.

Impact of Systemic Lupus Erythematosus (SLE) on Short-Term Outcomes of Cholecystectomy for Acute Cholecystitis: An Analysis of the US National Readmission Database, 2016-2020.

Journal: Journal of hepato-biliary-pancreatic sciences

Published: May 09, 2025

Survivors of Non-Hodgkin's Lymphoma: A Comparative Study on Patients With Vincristine-Induced Neuropathy and Their Quality of Life.

Survivors of Non-Hodgkin's Lymphoma: A Comparative Study on Patients With Vincristine-Induced Neuropathy and Their Quality of Life.

Journal: The journal of nursing research : JNR

Published: May 06, 2025

Assessment of the Relationship Between Positive Radial Margin and Prognosis in Patients with Gastric Adenocarcinoma.

Assessment of the Relationship Between Positive Radial Margin and Prognosis in Patients with Gastric Adenocarcinoma.

Journal: Cancers

Published: March 25, 2025

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step-up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study.

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step-up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study.

Journal: Cancer reports (Hoboken, N.J.)

Published: March 04, 2024

The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.

The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.

Journal: Therapeutic advances in medical oncology

Published: October 01, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026